Advanced Cell Diagnostics by Bio-Techne Establishes a New Benchmark in Spatial Biology with Protease-Free RNAscope Multiomics

Bio-Techne Corporation (NASDAQ: TECH) has unveiled a groundbreaking achievement, as its spatial biology brand, Advanced Cell Diagnostics (ACD), sets a new industry standard. The innovation comes in the form of a cutting-edge, protease-free RNAscope spatial multiomics workflow, designed for superior same-slide detection of protein and RNA biomarkers. This revolutionary workflow ensures unparalleled sensitivity and preservation of tissue morphology. Compatible with both manual and automated assays, ACD’s novel protease-free RNAscope workflow is seamlessly integrated into Bio-Techne’s recently introduced top-tier multiomics application on Lunaphore’s COMET platform.

Revolutionizing Spatial Biology: Bio-Techne’s ACD Unveils Protease-Free RNAscope Workflow for Simultaneous RNA and Protein Imaging

Bio-Techne Corporation’s spatial biology brand, Advanced Cell Diagnostics (ACD), has introduced a groundbreaking advancement with a novel, protease-free RNAscope spatial multiomics workflow. This innovative approach enables simultaneous imaging of RNA and protein biomarkers on the same tissue section, providing an unparalleled single-cell perspective of disease pathology and therapeutic response. This marks a significant leap forward compared to existing spatial technologies that are limited to the detection of either RNA or protein, often leading to the degradation of the alternate biomarker type.

The elimination of proteases traditionally used in RNA detection preserves both protein and RNA integrity, ensuring the conservation of tissue morphology. This advanced workflow facilitates the quantification of subcellular gene expression and simplifies image and data analysis for multiomic changes.

Kim Kelderman, Chief Operating Officer at Bio-Techne, expressed pride in achieving another milestone in spatial multiomics strategy. The protease-free RNAscope workflow has garnered positive feedback from customers who tested it with existing on-market RNAscope assays. The company anticipates offering this enhanced capability across its RNAscope portfolio later this year.

ACD, a pioneering force in spatial biology, has been delivering industry-leading single-molecule sensitivity and unmatched specificity with its patented RNAscope ISH technology for over a decade. With an extensive track record, including over 9,500 peer-reviewed publications and over 50,000 unique probes sold, RNAscope technology has played a pivotal role in spatially detecting a broad range of RNA subtypes from research to clinical applications.

The groundbreaking data will be presented at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting in Orlando, Florida, with activities taking place at the Lunaphore Suite, Curacao 4, from February 5-8. ACD scientist Ge-Ah Kim, Ph.D., will showcase additional technical advances in the codetection of RNA with proteins and protein-protein interactions using RNAscope on February 7 at poster #633 titled “Single-slide, in situ multiomic imaging of mRNA, protein, and protein-protein interactions in the tumor-immune microenvironment of bladder cancer patients.

Source link